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Abstract Chronic hepatitis B virus infection is an impor-
tant cause of liver-related morbidity and mortality, with
hepatocellular carcinoma being the most life-threatening
complication. Because of the highly variable clinical
course of the disease, enormous research efforts have been
made with the aim of revealing the factors in the natural
history that are relevant to hepatocarcinogenesis. These
include epidemiological studies of predisposing risk
groups, viral studies of mutations within the hepatitis B
viral genome, and clinical correlation of these risk factors
in predicting the likelihood of development of hepatocel-
lular cancer in susceptible hosts. This update addresses
these risks, with emphasis on the latest research relevant to
hepatocarcinogenesis.
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Introduction
Chronic hepatitis B (CHB) infection is a global problem
affecting nearly 400 million individuals worldwide. The
majority of those infected are ethnically of Asian and
African origin. Asians and Africans account for more than
80% of hepatitis B-related mortality, from hepatocellular
carcinoma (HCC) and cirrhosis. As the natural history of
CHB infection unfolds with ongoing clinical research, we
strive to elucidate the pathogenic mechanisms and carcino-
genesis behind hepatitis B infection and its chronic
sequelae. An exciting area of hepatitis B research focuses
on determining the risk factors of development of HCC.
This review focuses on the latest basic and clinical research
on various risk factors that have been identified in CHB-
infected individuals who develop HCC. A summary of
studies—mainly population studies, case-controls, cohort
studies, and genetic studies—are highlighted, with the
emphasis on the themes and mechanisms of hepatocellular
carcinogenesis.
Hepatitis B Virus and Carcinogenesis
Hepatitis B virus (HBV) infection has a highly variable
clinical presentation ranging from asymptomatic carrier
state to fulminant hepatic failure. CHB infection can lead to
cirrhosis, resulting in liver failure and HCC. There are
inherent barriers to studying the hepatitis B virology
because of the inability to culture HBV for in vitro studies.
The multifactorial and complex processes—from initial
infection to viral persistence, chronic hepatitis, and ulti-
mately to HCC—have yet to be fully unraveled. One of the
mechanistic pathways of HBV carcinogenesis includes
HBV integration into the host genome. This may lead to
chromosomal translocations, duplications, deletions, and
amplification of cellular DNA [1]. Subsequent intracellular
events regulated and mediated by the hepatitis B X gene
(HBx) products include regulatory proteins that affect
transcription and transactivation of proto-oncogenes with
modulation of cell signaling pathways. Similarly, proteins
from the pre-S2/S region have been implicated in HBV
carcinogenesis because HBx or pre-S2/S viral proteins have
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Furthermore, inhibition of DNA repair mechanisms may
culminate in mutations in the pre-core and core promoter
regions of the HBV viral genome, which have been shown
in various studies to correlate with a greater chance of
developing HCC. Because 80–85% of patients with HBV-
related HCC have underlying cirrhosis, chronic infection
with persistent and rapid regeneration of hepatocytes can
lead to accumulation of mutations that predispose the
hepatocytes to malignant transformation. In HBV-related
HCC, chromosomal mutations are more common than in
non–HBV-related HCC [2]. Likewise, a variety of genetic
alterations and marked heterogeneity of gene expression
profiles have been documented in HCC cases. The close
connection between cirrhosis and the development of HCC
is similar to alcohol- and hepatitis C-related HCC.
However, the absence of cirrhosis in 15–20% of HBV-
related HCC highlights the direct oncogenic properties of
the virus itself.
Host Risk Factors
Host and demographic factors associated with a higher
risk of developing HCC include age greater than 40 years,
male gender, Asian race, and various other lifestyle or
modifiable environmental risk factors such as smoking,
alcohol consumption, ingestion of aflatoxin B1,a n d
family history of HCC. A strong association between
individuals greater than 40 years old and HBV-related
HCC has been demonstrated by various cohort studies [3].
Compared to the 30 to 39 years age group, the relative
risk of HCC development in the 40 to 49 years group is
3.6 to 5.4 and in the 60 years or older group is 8.3 to
17.7 [3]. Male gender is also associated with an increased
r i s ko fH C Cc o m p a r e dt ow o m e ni nt w ol a r g eT a i w a n e s e
studies [4, 5￿]. Asian race is associated with a high
prevalence of HBV-related HCC. More than 70% of
newly diagnosed HCC cases occur in Asia, where 75%
of CHB-infected patients reside. (An exception is Japan,
where HCV is the etiology in 80% of HCC cases [6]). In
North America, ethnic Asians and African-Americans are
more likely to develop HCC from hepatitis B infection
when compared to Caucasians [7]. In another large
Taiwanese population study, first-degree relatives, partic-
ularly siblings, are more likely to develop HCC, with a
multivariate-adjusted rate ratio of 2.4 compared to non-
HCC controls [8]. Other modifiable demographic factors
that predispose HBV-infected individuals to have a higher
chance of developing HCC include heavy regular alcohol
consumption [9], consumption or exposure to aflatoxins
[10], and diabetes mellitus, which may be related to
steatohepatitis [11].
Host Response to HBV infection
The various stages of human infection, immunotolerance,
immunoclearance, and late/residual phases are characterized
by changes in hepatitis B early antigen (HBeAg), alanine
aminotransferase (ALT), and HBV DNA levels. The host
immune response is mainly cytotoxic T-lymphocyte-
mediated and drives the events that may lead to ultimate
viral clearance. The immunotolerance phase is associated
with HBeAg-positive state, normal ALT, and high viral load.
The immunoclearance phase occurs with fluctuating ALT
levels and often correlates with HBeAg seroconversion. At
this time, the HBV DNA may also be reduced to lower
levels, and less frequently, to undetectable levels. In the
chronic late/residual phase, mild ALT fluctuations associated
with viremia are often seen, with a significant proportion of
patients progressing to established cirrhosis. The levels of
ALT have been shown to be poor predictors of progression
of liver disease to cirrhosis and HCC. In a Korean study of
individuals with no known liver diseases, high “normal”
ALT values were associated with increased liver-related
mortality [12]. In a study of 3,233 Chinese patients with
CHB, it was shown that ALT levels of 0.5 to 1.0 times the
upper limit of normal (ULN) and 1 to 2 times the ULN were
associated with increased risk of developing cirrhosis
complications and HCC compared with patients with ALT
levels less than 0.5 times the ULN (P<0.0001 for both
groups) [13]. Cirrhosis is another virus-mediated, host-driven
response. Cirrhosis has been consistently shown to predict
the development of HCC, as exemplified by cross-sectional
or case-cohort studies [13, 14].
HBV Risk Factors
Many potential virological factors may be associated with a
higher risk of developing HCC. HBeAg, HBV DNA load,
viral genotype, and pre-core and core promoter region
mutations have all been studied. HBeAg positivity reflects
active viral replication and has been associated with higher
incidence of HCC [15]. However, it should be noted that
two thirds of patients with HCC are already positive for
antibody to HBeAg [13]. In the landmark Risk Evaluation
of Viral Load Elevation and Associated Liver Disease/
Cancer-Hepatitis B (REVEAL-HBV) study, more than
3,500 HBsAg-positive adults aged 30 to 64 years were
followed from 1991 to 2004 for the incidence of cirrhosis
and HCC. This study documents that the higher the viral
load, the more likely the chance of progression to cirrhosis
and HCC, independent of HBeAg status and ALT levels
[16]. In another recent study conducted in Japan, in patients
over the age of 40 years, HBV DNA viral load again was
confirmed to be an important risk factor [17].
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the HBV genome are associated with a higher risk of HCC
development. The HBV genome consists of four over-
lapping open reading frames (ORFs) encoding the surface,
core, X, and polymerase proteins. The HBV core promoter
region includes the basal core promoter (nucleotides 1751–
1769) and the enhancer II (nucleotides 1636–1744), which
overlaps with the X ORF (nucleotides 1374–1835). The
core promoter is regulated by enhancer II (and to some
extent, enhancer I) and controls the transcription of pre-core
mRNA and pre-genomic RNA. In the basal core promoter
region, A1762T/G1764A nucleotide substitutions, particu-
larly when occurring as a double mutation, are shown to be
associated with a higher chance of HCC, in genotypes B
and C [18]. Furthermore, these mutations can be detected
in the plasma up to 8 years before HCC diagnosis,
signifying a possible role as serum biomarkers for
predicting HCC occurrence [19]. However, in a recent
cross-sectional study from Qidong, China, 852 hepatitis B-
infected subjects were followed (for up to 7 years) with
annual blood tests for HBV gene sequencing. Fifty-eight
subjects who developed histologically proven HCC were
compared with 71 subjects with chronic hepatitis who did
not develop HCC. Both T1762/A1764 mutations were
frequently seen across both groups; there was no differ-
ence in the prevalence of these mutations between the two
groups (P>0.05). However, the adjacent nucleotide muta-
tions C1766T and T1768A were significantly higher in
HCC patients when compared to hepatitis B controls [20].
Of the 58 cases of HCC with identified HBV sequences,
22.4% possessed triple mutations compared to only 7% in
the hepatitis B controls (P<0.05). T1766 and A1768
mutations occurred more frequently at a later time point
before HCC detection, which may indicate a crucial role in
carcinogenesis.
The possible carcinogenic roles of other HBV mutations
have been studied. Present evidence does not suggest that
the precore mutations, a G1896A mutation abolishing the
production of HBeAg, play an important role in hepato-
carcinogenesis [21￿￿]. However, a recent meta-analysis
showed that C1653T in the enhancer II region and
T1753V of the X region are linked with an increased risk
of HCC [22]. Another recent study from China analyzed
196 HCC patients (with 323 controls) and showed that pre-
S deletion, and T1762/A1764 double mutations, are
independent risk factors for HCC [23]. A novel F141L
mutation in the pre-S2 region is also identified as a risk
factor for HCC in a Korean study of genotype C patients
[24]. A study performed in Thailand comparing the HBV
DNA sequences of HCC versus non-HCC hepatitis B
patients showed that A1762T/G1764A and G1899A muta-
tions were independently associated with a higher risk of
HCC after multiple logistic regression analysis [25].
Although G1899A mutations have not been consistently
demonstrated in HCC cohorts in other studies [26], this
mutation and its association with other, better known,
mutations may play a synergistic role in hepatocarcino-
genesis. In addition to identifying mutations in the HBV
genome that predispose patients to HCC occurrence, a
recently published study showed that HBV DNA level
(>3.0×10
7 copies/g) and basal core promoter A1762T/
G1764A mutation are both independently predictive of
postoperative increased survival in surgically operated
HCC patients, whereas a small pre-S deletion between
codons 107 and 144 heralds a poorer postoperative
prognosis [27￿]. The identification of pre-S2 deletion and
its significance is gaining in importance. In a Taiwanese
study involving pediatric patients with HCC, the sera of
HCC patients had a much higher rate of pre-S deletion
(nearly all were in S2 region and more commonly seen in
genotype C) than non-HCC controls. The odds ratio is
36.69 (P=0.015), highlighting the fact that even in pediatric
age groups, pre-S mutations are potentially carcinogenic
[28]. Despite the identification of multiple nucleotide
substitutions, these mutations and their mechanism of
carcinogenesis remain largely unknown. [29].
HBx Protein
The HBx regulatory protein is encoded by the X gene
with multiple functions. This small protein is a transcrip-
tional activator and is essential for HBV viral replica-
tions and infection. HBx has been shown to promote
tumor formation in transgenic mice [30]. In humans, HBx
has pleiotropic activities on cell cycle regulation, signaling
pathways, and DNA repair. Its transactivation function
may play a crucial role in hepatic carcinogenesis because a
large number of signaling pathways, cellular genes, and
inflammatory and regulatory mediators are involved.
Studies have shown that X gene mutations are linked with
increased risk of hepatocellular carcinoma [31, 32]. The
impact of basal core promoter mutations has an indirect
effect on the HBx protein. A three-amino acid substitution
(lysine to methionine, valine to isoleucine, and phenylal-
anine to tyrosine at aa 130–1 3 2 )c a nl e a dt or e d u c e d
growth-inhibitory effects of HBx [20]. In a recent review
published by Neuveut et al. [33￿], HBx and its regulation
of transcription indirectly via cellular signaling pathways
(eg, nuclear factor-κB, mitogen-activated protein kinase,
and janus kinase/signal transducer and activator of
transcription pathways) are elegantly outlined. However,
the HBx regulatory protein and its mechanisms of
tumorigenesis in humans remain largely understudied,
and further research is needed to define its oncogenic role
in HCC development.
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Currently, there are eight major HBV genotypes (A to H) as
determined by a genomic sequence divergence of greater
than 8%. Different genotypes are found in various parts of
the world. Because genotypes B and C are most commonly
seen in Asia, these two genotypes have been studied in
greater detail. Different HBV genotypes have distinct
patterns of viral mutations in the preS and the enhancer
II/basal core promoter/precore regions. The preS deletion
mutations and core promoter mutations are more frequently
found in genotype C than in genotype B patients [34, 35￿￿].
It is also generally known that genotype C carries a
higher chance of cirrhosis and subsequently HCC. A
recent study showed that genotype C, viral load greater
than 10
4 copies/mL, A2962G, preS2 start codon mutation,
T105C, T1753V, and A1762T/G1764A are independently
associated with increased risk of HCC [36]. However,
genotype B has been linked to a younger HCC profile, in
w h i c hc i r r h o s i sw a sl e s sc o m m o n l ys e e n[ 37]. Yet other
studies have shown that genotype B and C do not differ in
the risk of development of HCC [38, 39]. The apparent
differences may be due to the higher prevalence of core
promoter mutations (which is an independent risk factor
for HCC) seen in genotype C patients. Because of the
smaller number of individuals with the other major HBV
genotypes (A, D–H), cohort studies defining the muta-
tional phenotypes are still scarce. Table 1 summarizes the
known host and viral risk factors for HCC development in
patients with CHB.
Risk Factors and Predictive Scores
Predictive scores have been designed to give the
clinician more quantitative measurements in guiding
treatment and HCC surveillance. In a case-cohort study
of 820 treatment-naive patients with CHB, the 5-year
prevalence of HCC was 4.4% and the 10-year prevalence
was 6.3% [40]. Cox regression analysis showed that male
gender (P=0.025, RR 2.98), increasing age (P<0.001, RR
1.07), higher HBV DNA levels (P=0.02, RR 1.28), core
promoter mutations (P=0.007, RR 3.66), and presence of
cirrhosis (P<0.001, RR 7.31) were independent risks for
the development of HCC. A risk score was derived from
the above factors: the Guide with Age, Gender, HBV
DNA, Core promoter mutations, and Cirrhosis (GAG-
HCC) score. The formula was 16 * sex (male=1, female=
0) + age (in years) + 3 * HBV DNA (copies/mL in log) +
19 * core promoter mutations (mutant=1, wild type=0) +
30 * cirrhosis (presence=1, absence=0). The optimal cut-
off of the HCC score for the prediction of 5- and 10- year
development of HCC was 101. The sensitivity using this
cut-off was 84.1% (at 5 years) and 88.0% (at 10 years).
The specificity was 76.2% (at 5 years) and 78.7% (at
10 years). The inherent limitations of this predictive
scoring model lie in its oversimplification and synergistic
effects (rather than simply additive) of multiple and
confounding risk factors. In addition, the core promoter
mutation analysis may not be available in non–research-
based laboratories. With recent research highlighting the
importance of other newly identified mutations (eg, the
pre-S deletion mutations), the score should be revised for
more accurate risk prediction.
Other clinical scoring systems have been devised and
validated using simple clinical parameters, without the
need for determining HBV DNA mutations or HBV
genotypes. For example, Yang et al. [41] derived a
nomogram (from a study with more than 3,600 patients)
using parameters of sex, age, family history of HCC,
alcohol consumption habit, serum ALT level, HBeAg
status, serum HBV DNA level, and HBV genotype to
predict the risk of development of HCC at 5 and 10 years.
Wong et al. [42] evaluated more than 1,000 patients and
determined five clinical parameters that independently
predicted HCC development: age, albumin, bilirubin,
HBV DNA, and the presence of cirrhosis. A prediction
scoring system was formulated and validated with another
cohort with high accuracy and predictability. The applica-
tion of these scoring systems using clinical and virologic
parameters should play an important role in guiding
clinicians’ individual patient management.
Table 1 Risk factors for development of hepatocellular carcinoma in
patients with chronic hepatitis B
Risk factor Strength of association
Host
Male ++
Age>40 y ++
Family history +
Regular alcohol consumption +/-
Host-viral interaction
ALT levels +
Cirrhosis ++
Viral
High HBV DNA levels ++
Genotype C +
Precore mutation −
Core promoter mutations ++
Pre-S +
HBx +
−none, +/- possible association, + known association, ++ strong
association, ALTalanine aminotransferase, HBV hepatitis B virus, HBx
hepatitis B X gene
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This review highlights the main important risk factors of
HCC development, with particular focus on demographics,
host, and viral factors. The most susceptible host would be
an Asian male aged older than 40 years with a long-
standing history of hepatitis B infection. High levels of
circulatory HBV DNA coupled with the presence of clinical
cirrhosis are further disease-related risk factors. The
importance of recognizing particular naturally occurring
mutations such as pre-S deletions, core promoter mutations
that may or may not overlap with the X region, and novel
mutations that are being discovered cannot be overempha-
sized. Important mutations identified in cohort studies may
serve as potential serum biomarkers in susceptible individ-
uals. HBV genotype C remains an important association
with HCC despite the conflicting data available. Scoring
systems to predict HBV-related HCC have been developed
and may be refined with further elucidation of the
mechanisms of HCC carcinogenesis.
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